How and when to take prostate biopsies

European Urology, Supplement

Volumn 1, Issue 6, 2002, Pages 15-20

  Vanderkerken, Jan ^a   De la Rosette, Jean ^a   Laguna, Pilar ^a   Debruyne, Frans ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biopsy; Cancer; DRE; Imaging; Number of biopsies; PIN; Prophylaxis; Prostate; PSA; Repeat biopsy; Ultrasound

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY;

EID: 0036765793     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1569-9056(02)00052-0     Document Type: Article

References (27)

1. Isen K, Kupeli B, Sinik Z, Sozen S, Bozkirli I. Antibiotic prophylaxis for transrectal biopsy of the prostate: a prospective randomized study of the prophylactic use of single dose oral fluoroquinolone versus trimethoprim-sulfamethoxazole. Int Urol Nephrol 1999;31:491-5.
2. Lindert KA, Kabalin JN, Terris MK. Bacteremia and bacteriuria after transrectal ultrasound guided prostate biopsy. J Urol 2000;164:76-80.
3. Carey JM, Korman HJ. Transrectal ultrasound guided biopsy of the prostate. Do enemas decrease clinically significant complications? J Urol 2001;166:82-5.
4. Vaidya A, Soloway MS. Periprostatic local anesthesia before ultrasound-guided prostate biopsy: an update of the Miami experience. Eur Urol 2001:40:135-8.
5. Wu CL, Carter HB, Naqibuddin M, Fleisher LA. Effect of local anesthetics on patient recovery after transrectal biopsy. Urology 2001;57:925-9.
6. Chiari R, Harzmann R. Perineal and transrectal needle biopsy of the prostate (author's translation). Urologe A 1975;14:296-8.
7. Kuligowska E, Barish MA, Fenlon HM, Blake M. Predictors of prostate carcinoma: accuracy of gray-scale and color Doppler US and serum markers. Radiology 2001;220:757-64.
8. Sedelaar JP, van Leenders GJ, Hulsbergen-van de Kaa CA, van der Poel HG, van der Laak JA, Debruyne FM, et al. Microvessel density: correlation between contrast ultrasonography and histology of prostate cancer. Eur Urol 2001;40:285-93.
9. Frauscher F. Klauser A, Halpern EJ, Horninger W, Bartsch G. Detection of prostate cancer with a microbubble ultrasound contrast agent. Lancet 2001;357:1849-50.
10. Bogers HA, Sedelaar JP, Beerlage HP, de la Rosette JJ, Debruyne FM, Wijkstra H, et al. Contrast-enhanced three-dimensional power Doppler angiography of the human prostate: correlation with biopsy outcome. Urology 1999;54:97-104.
11. Sedelaar JP, van Roermund JG, van Leenders GL, Hulsbergen-van de Kaa CA, Wijkstra H, de la Rosette JJ. Three-dimensional grayscale ultrasound: evaluation of prostate cancer compared with benign prostatic hyperplasia. Urology 2001;57:914-20.
12. Sedelaar JP, Goossen TE, Wijkstra H, de la Rosette JJ. Reproducibility of contrast-enhanced transrectal ultrasound of the prostate. Ultrasound Med Biol 2001;27:595-602.
13. Kuhn M, Huttmann P, Spielhaupter E, Gross-Fengels W, Schreiter F. Clinical value of native and contrast enhanced MRI in staging prostatic carcinoma before planned radical prostatectomy. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2001;173:595-600.
14. Hodge KK, McNeal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989;142:71-4.
15. Aus G, Bergdahl S, Hugosson J, Lodding P, Pihl CG, Pileblad E. Outcome of laterally directed sextant biopsies of the prostate in screened males aged 50-66 years. Implications for sampling order. Eur Urol 2001;39:655-61.
16. Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995;45:2-12.
17. Manseck A, Guhr K, Froehner M, Hakenberg OW, Wirth MR Morbidity and discomfort of ten-core biopsy of the prostate evaluated by questionnaire. Urol Int 2001;66:197-200.
18. Emiliozzi P, Longhi S, Scarpone P, Pansadoro A, DePaula F, Pansadoro V. The value of a single biopsy with 12 transperineal cores for detecting prostate cancer in patients with elevated prostate specific antigen. J Urol 2001;166:845-50.
19. Mazal PR, Haitel A, Windischberger C, Djavan B, Sedivy R, Moser E. Spatial distribution of prostate cancers undetected on initial needle biopsies. Eur Urol 2001;39:662-8.
20. Djavan B, Zlotta A, Remzi M, Ghawidel K, Basharkhah A, Schulman CC, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: a prospective study of 1051 men. J Urol 2000; 163:1144-8.
21. Luboldt HJ, Swoboda A, Borgermann C, Fornara P, Rubben H. Clinical usefulness of free PSA in early detection of prostate cancer. Onkologie 2001;24:33-7.
22. Schroder FH. Diagnosis, characterization and potential clinical relevance of prostate cancer detected at low PSA ranges. Eur Urol 2001;39(Suppl 4):49-53.
23. Potter SR, Homiger W, Tinzl M, Bartsch G, Partin AW. Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. Urology 2001;57:1100-4.
24. Boccon-Gibod L. Rising PSA with a negative biopsy. Eur Urol 2001;40(Suppl 2):3-8.
25. Djavan B, Zlotta AR, Ekane S, Remzi M, Kramer G, Roumeguere T, et al. Is one set of sextant biopsies enough to rule out prostate cancer? Influence of transition and total prostate volumes on prostate cancer yield. Eur Urol 2000;38:218-24.
26. Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol 2001;166:856-60.
27. Djavan B, Ravery V, Zlotta A, Dobronski P, Dobrovits M. Fakhari M, et al. Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? J Urol 2001;166:1679-83.